Skip to main content
Clinical Trials/NCT01188525
NCT01188525
Completed
Phase 1

Pharmacokinetic of Ten Parent Drugs and Their Metabolits in Order to Characterise Individual Metabolic Profile

Institut National de la Santé Et de la Recherche Médicale, France1 site in 1 country10 target enrollmentAugust 1, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy Volunteers
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment
10
Locations
1
Primary Endpoint
Pharmacokinetic parameters
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

The study aims to descibe the pharmacokinetics of 10 substrates of enzymes involved in drug metabolism and their metabolites, after administration singly and simultaenously at predefined doses in 10 health volunteers.

Detailed Description

The aim of this study is to test the administration of combination of substrates and thereby to characterise simultaneously the main enzymes and transporters involved in drug metabolism. The doses of substrates administered will first assessed in terms of safety and their appropriateness for determination of pharmacokinetic parameters. Ten volunteers will be used, this number having been defined in view of the aims of this proof-of-concept pilot study,ie,safety and determination of pharmacokinetic parameters. The number was not the result of statistical calculation.

Registry
clinicaltrials.gov
Start Date
August 1, 2010
End Date
July 1, 2011
Last Updated
8 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • healthy volunteers

Exclusion Criteria

  • pregnancy

Outcomes

Primary Outcomes

Pharmacokinetic parameters

Time Frame: one week

The aim endpoint is based on the main pharmacokinetic parameters of each subject for all substrates and all metabolites. These main parameters are the area under the curve (AUC), the maximum concentration (Cmax), the half-life (T1/2)and the ratios of AUCs of the substrate and metabolites

Secondary Outcomes

  • Tolerance of the concomittant administration of the 10 drugs: 1/number of volunteers with grade 4 adverse events 2/ number of volunteers with any adverse event, (grade 1 to grade 4)(one week)
  • pharmacokinetic(one week)
  • Genotypes(one month)

Study Sites (1)

Loading locations...

Similar Trials